<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00886977</url>
  </required_header>
  <id_info>
    <org_study_id>YAM80-01</org_study_id>
    <nct_id>NCT00886977</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of YAM80 in Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>Pilot-Study of YAM80 in Amyotrophic Lateral Sclerosis. Evaluation of the Efficacy and Safety of YAM80 in Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yoshino Neurology Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yoshino Neurology Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy and safety are evaluated when YAM80 is administered orally to the patients of
      Amyotrophic Lateral Sclerosis (ALS).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ALSFRS-R</measure>
    <time_frame>24w + follow-up period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>24w and the follow up period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Manual Muscle Testing</measure>
    <time_frame>24w + follow-up period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip/pinch strength</measure>
    <time_frame>24w + followup period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function (forced vital capacity)</measure>
    <time_frame>24w + follow-up period</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YAM80</intervention_name>
    <description>Oral administration, 2 to 6 mg, once a day.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged between 25 and 65 years

          -  ALS patients who can visit the clinic for six months

          -  Forced Vital Capacity (FVC) &gt; 70%

          -  Patients who can walk by themselves

          -  Change in ALSFRS-R score from -1 to -4 during 12 weeks before the initial
             administration

          -  Patients who are willing to give informed consent

        Exclusion Criteria:

          -  Tracheotomy and invasive ventilation

          -  Pregnant or possibly pregnant female patients

          -  Female patients of childbearing potential who cannot practice contraception during and
             two years after the administration, and male patients who cannot practice
             contraception during and six months after the administration

          -  Patients with clinically significant conditions such as cardiovascular, respiratory,
             haematological, and renal diseases.

          -  Patients who are being treated with investigational drugs

          -  Patients who are treated with other ALS drugs within 2 weeks prior to the first
             administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiide Yoshino, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yoshino Neurology Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yoshino Neurology Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2009</study_first_submitted>
  <study_first_submitted_qc>April 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2009</study_first_posted>
  <last_update_submitted>October 22, 2010</last_update_submitted>
  <last_update_submitted_qc>October 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hiide Yoshino, Clinic Director</name_title>
    <organization>Yoshino Neurology Clinic</organization>
  </responsible_party>
  <keyword>ALS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

